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Background: The objective was to describe symptom assessment scales that have been used in children with
cancer.
Methods: We conducted electronic searches of OVID Medline and EMBASE in order to identify all symptom
assessment scales that have been used in pediatric cancer. Two reviewers abstracted information from each
identified study. Data collected included study demographics and information related to the instrument and
children enrolled. We also collected information about the purpose of instrument administration and whether
treatment was altered as a result of this information.
Results: Fourteen studies were identified which evaluated eight different symptom assessment scales. Eight studies
used child self-report and all studies included children on active treatment for cancer although 4 studies also
included children following completion of treatment. The most common purpose of instrument administration was
to measure the prevalence of symptom burden (n = 8). None of the 14 studies used the scale to screen for
symptoms and none changed patient management on the basis of identified symptoms.
Conclusions: We failed to identify any symptom assessment scales that were used as a symptom screening tool.
There is a need to develop such a tool for use in children with cancer.
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Cure rates for pediatric cancer are approaching 80% but
the costs of this progress include a high prevalence of
symptoms during treatment [1-3] and a high rate of
chronic health conditions following completion of treat-
ment [4]. It is important to identify and control symp-
toms in order to maximize quality of life (QoL) and
reduce morbidity. Furthermore, there is some evidence
that reduction in symptoms may improve future psycho-
social functioning [5].
Within the adult oncology setting, screening of
symptoms through patient self-report has been identi-
fied as an important priority [6-9]. Consequently,
much effort has been focused on symptom screening
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reproduction in any medium, provided the orOntario have culminated in the wide-spread use of a
symptom screening tool based upon the Edmonton
Symptom Assessment Scale (ESAS) [10]. The ESAS is
a validated symptom screening tool which asks adult
patients to rate the severity of nine common symp-
toms including pain, anxiety and nausea. In a satisfac-
tion survey conducted in 2010 among 2,921 patients,
87% of respondents thought that the ESAS was an im-
portant tool for letting healthcare providers know how
they feel [11]. However, no initiative to identify a com-
mon symptom screening tool has been undertaken in
pediatric oncology.
It is important to distinguish between QoL instru-
ments and symptom assessment scales as these are
closely intertwined but distinct. QoL is a multidimen-
sional construct grounded in the World Health Organi-
zation’s definition of health in which health is not
merely the absence of disease, but rather, a state of
complete physical, mental and social well-being [12].
Many QoL instruments include symptom assessmentLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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QoL rather than the symptom specifically. In contrast,
the purpose of symptom assessment scales is to identify
and measure symptom burden.
In order to identify an optimal symptom screening
tool that may be used in children receiving cancer treat-
ment, it would first be important to describe all symp-
tom assessment scales that have been used in this
population. This process would allow one to determine
if any of these scales may be used as a symptom screen-
ing tool or if one could be adapted for this purpose.
Consequently, the objective was to describe symptom
assessment scales that have been used in children receiv-
ing cancer treatment.Methods
Data sources and searches
We used the Strengthening the Reporting of Observa-
tional Studies in Epidemiology (STROBE) guideline for
reporting observational studies [13] to develop a proto-
col for this systematic review. We conducted electronic
searches of OVID Medline (1948 to December 19, 2011)
and EMBASE (1980 to December 19, 2011). Appendix 1
illustrates the search strategy.Study selection
We included studies that used a symptom assessment
scale to measure multiple symptoms. Exclusion criteria
were: (1) Not published as a full article (conference pro-
ceedings excluded); (2) Pediatric data not available; (3)
Population not cancer; (4) Symptoms retrospectively
reported for a period that did not include current symp-
toms (i.e. studies which used a recall period such as
1 week and 1 month were included while studies that
only evaluated symptoms that occurred in the past and
did not evaluate recent or current symptoms were
excluded); (5) Purpose of the study was only to evaluate
a translated version; (6) Not a study; (7) Duplicate publi-
cation; (8) Symptom assessment scale not appropriate
because: a) only included psychological symptoms; b)
included items that are not symptoms; or c) only mea-
sured a single symptom or (9) Not in English.
One reviewer (LS) evaluated the titles and abstracts
identified by the search strategy and any potentially rele-
vant publication was retrieved in full. Two independent
reviewers (MCE and LS) assessed for eligibility. Final in-
clusion into the review was by agreement of both
reviewers. Agreement between reviewers was evaluated
using the kappa statistic. Strength of agreement as evalu-
ated by the kappa statistic was defined as slight (0.00-
0.20), fair (0.21-0.40), moderate (0.41-0.60), substantial
(0.61-0.80) or almost perfect (0.81-1.00) [14].Data extraction, quality assessment and analytic
approach
Two reviewers (MCE and LS) extracted data from
included trials using a standardized data collection form.
Data collected included trial demographics (year of pub-
lication, country in which study was conducted, language
in which the instrument was administered), name of the
instrument, information related to instrument adminis-
tration (how administered, proxy or self-report, number
of times administered), information about the number
and characteristics of children enrolled (age, on/off ac-
tive treatment) and the five most common symptoms
identified. We also collected information about the pur-
pose of instrument administration, whether treatment
was altered as a result of this information and whether
there were difficulties with administration for studies in
which child self-report was used. We defined screening
for this review as whether the study specifically reported
abnormal results to clinicians or altered treatment be-
cause of identified symptoms. We then described the
details of the identified scales.
Study quality was assessed using a modified version of
an instrument previously developed to describe quality in
studies of prognosis [15]. This instrument examines four
potential sources of bias: study participation, study attri-
tion, confounding variables and measurement of out-
comes. Given that study attrition is less relevant in this
setting, we excluded this item. Each element was rated as
having low, medium or high risk of bias for each study.
The analytic approach was purely descriptive and the
data were not synthesized.
Results
Figure 1 illustrates the flow diagram of trial identifica-
tion and selection. A total of 686 titles and abstracts
were reviewed, and 34 full articles were retrieved. Of
these, 14 satisfied pre-defined inclusion criteria. Reasons
for excluding 20 articles are provided in Figure 1. The
reviewers had perfect agreement on articles for inclusion
(kappa = 1.00). The number of studies that illustrated
low risk of bias was as follows: study participation
(n = 6), confounding variables (n = 4) and measurement
of outcomes (n = 7).
Table 1 illustrates the characteristics of the included
studies. Of the 14 studies, [3,16-28] 6 were conducted in
the United States[18-20,23,25,26] and 3 were conducted
in the United Kingdom [16,24,28]. Twelve were con-
ducted in English [3,16-20,23-28] and 2 were conducted
in other languages in addition to English (Spanish [18]
and Swedish [3]). Instruments were administered in per-
son only (n = 10), by telephone only (n = 1) or in multiple
formats (n = 3). None of the 14 studies used the symp-
tom assessment scale to screen for symptoms and no
study changed patient management on the basis of
686 Potentially Relevant 
References Identified and 
Screened 
652 Excluded by Review of 
Abstracts 
Did not fulfill inclusion/exclusion 
34 Full Articles Retrieved for 
Detailed Evaluation 
20   Excluded 
 13  Pediatric data not available 
   1  Symptoms solely psychological  
   3  Not studies (ie. systematic review) 
   2  Duplicate publication   
   1  Not in English 
14 Studies Included 
Figure 1 Flow diagram of study identification and selection.
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strument administration was to describe the degree of
symptom burden in their population (n = 8).
Of the 11 studies that described the most common
symptoms, the most frequently cited symptoms appearing
on the 5 most common lists were: fatigue (n=9), nausea
(n=7), pain (n=5), drowsiness (n= 4), and anorexia
(n=3). There were 6 studies that described the mean num-
ber of symptoms per patient in their cohort; this number
ranged from 1.9 to 12.7. Three of the studies which usedTable 1 Characteristics of studies that used a symptom assess
Author Year Instrument Mean age in years ±
SD or (range)
Baggott[18] 2011 MSAS 10-18 14.7 ± 2.8
Wu[19] 2011 SDS NS
Gibson[16] 2010 ASyMS-YG 15* (13–18)
Poder[3] 2010 MSAS 10-18 NS
Walker[20] 2010 MSAS 7-12 14.2 + 2.7
Dupuis[17] 2009 Unique 9.4 ± 6.8
Sitaresmi[21] 2009 Unique 6* (2–16)
Yeh[22] 2009 MSAS 10-18 14.2 + 2.2
Williams[23] 2006 TRSC-C 10.4 ± 6.1
Collins[24] 2002 MSAS 7-12 9.6 (7–12)
Hinds[25] 2002 SDS 15.5 ± 2.1
Collins[26] 2000 MSAS 10-18 14 (10–18.2)
Berard[27] 1998 RSCL 16.9
Eiser[28] 1997 RSCL 14.5 (4–19)
*Median; **Timing refers to whether instrument was administered during active tre
***Instrument administered once or more than once.
Abbreviations: ASyMS-YG Advanced Symptom Management System – Young, MSAS
Therapy-related Symptom Checklist, RSCL Rotterdam Symptom Checklist, SD standachild self-report noted that children sometimes needed as-
sistance or clarification of questions [19,24,26].
Table 2 illustrates the details of the eight identified
instruments including the number of items, description
of items for scales that included < 15 items, dimensions
and scale types.
Discussion
We identified 14 studies that used eight different symp-
tom assessment scales to measure symptoms in childrenment scale in pediatric oncology
Number
enrolled
Respondent Timing ** Once or
multiple ***
66 Child During Multiple
40 Child During Once
27 Child During Multiple
292 Parent During Multiple
51 Child During Multiple
200 Parent During Once
61 Parent During Once
144 Parent Both Once
11 Parent During Once
149 Child Both Multiple
77 Child During Multiple
160 Child Both Multiple
43 Child During Multiple
47 Parent Both Once
atment only or both during and following completion of chemotherapy;
Memorial Symptom Assessment Scale, SDS Symptom Distress Scale, TRS-C
rd deviation, NS not stated.
Table 2 Features of the identified symptom assessment scales
Instrument Number of items Items for those with < 15 Items Dimensions Type of scale




3 or 4 point
Likert-type scales






MSAS 7-12[24] 8 Lethargy, sadness, itchiness, pain,
worry, anorexia, nausea, insomnia
3: Frequency, severity
and distress
3 or 4 point
Likert-type scales
MSAS 10-18[26] 30 3: Frequency, severity
and distress
4 or 5 point
Likert-type scales
RSCL[29] 39 1: Bother Mainly 4 point
Likert-type scales
SDS[25] 10 Sleep, feeling, tiredness, appearance,
appetite, ability to get around pain, nausea,
bowel movements, concentration
1: Distress 5 point Likert-type
scales
Sitaresmi[21] 13 Nausea, vomiting, abdominal pain, mouth
ulcers, increased appetite, decreased appetite,
infections, excessive weight gain, hair loss,






TRSC-C[23] 23 1: Severity 5 point Likert-type
scales
Abbreviations: ASyMS-YG Advanced Symptom Management System – Young; MSAS Memorial Symptom Assessment Scale, RSCL Rotterdam Symptom Checklist,
SDS Symptom Distress Scale, TRSC-C Therapy-related Symptom Checklist – Child.
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to describe the prevalence of symptom burden. None
were used as a symptom screening tool and none were
used to influence patient management. Consequently,
there is an absence of symptom screening tools which
have been used in children with cancer.
Measuring symptom severity in children is critical.
Children undergoing cancer treatment suffer and may
only seek help when symptoms become severe [16,30].
In one study in which children 13–18 years of age com-
pleted an electronic version of a symptom questionnaire,
participants noted that self-reporting symptoms was re-
assuring, made them feel more in control, helped them
to remember their symptoms and allowed them to see
how symptoms changed over time [16].
Identifying a feasible and clinically useful symptom
screening tool is important. Symptom screening instru-
ments could be used by patients in routine clinical prac-
tice in order to identify problems and focus the families’
and healthcare providers’ attentions on symptom control.
These instruments may also be used to determine symp-
tom prevalence and thereby inform the prioritization of
clinical patient services and/or research resources. In con-
sidering an ideal screening instrument, the scope of symp-
toms should include the most important symptoms to the
patient. The instrument should take into account the per-
spective of the patient’s family regarding symptom impact,
be applicable to children of all ages and have adequate
psychometric properties such as reliability and validity.
Both parent-proxy versions and child self-report versions
would be important to address the needs of children ofdifferent ages and cognitive abilities. In order to be feasible
in clinical practice, a brief screening tool is likely to be
more successful than lengthy assessment scales.
Once a feasible and clinically useful screening tool is
identified for pediatric cancer, a future step could be to
identify, adapt or develop evidence-based guidelines for
the management of each symptom included in the tool.
Such a system could improve patient/family self-
management and improve the ability of healthcare pro-
fessionals to standardize monitoring and care.
Our study has important limitations. First, we only
included studies published in the English language. The
rationale for this decision is that our research plan is to
first identify or adapt a symptom screening tool for use in
English with later translation into other languages. Second,
it is possible that there are symptom screening tools being
used in practice that have not been evaluated in the peer-
reviewed literature. Another limitation of our study is the
exclusion of scales which address psychosocial symptoms
alone. A final limitation is that our review excluded single
symptom scales. Although these scales are extremely im-
portant in clinical practice and research, they do not ad-
dress our goal of identifying a scale which could be used
as a symptom screening instrument or adapted for this
purpose. A future goal will be to examine the eight symp-
tom assessment scales identified in this review and deter-
mine if one of these could be used as a symptom
screening tool or if one could be adapted for this purpose.
Such a goal would likely be best accomplished using a
consensus methodology among a multi-disciplinary group
of experts in pediatric oncology supportive care.
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In conclusion, we performed a systematic review of
symptom assessment scales and identified eight instru-
ments which have been used in children with cancer;
none were used for the purpose of screening of symp-
toms or altered care. Identification or development of a
symptom screening tool in pediatric oncology should be
a priority.
Appendix 1
Details of the Literature Searches.
Ovid MEDLINE(R) 1948 to Present
1. (Symptom* adj2 (Scale* or instrument* or screen* or
measure* or tool or tools)).mp. (9775)
2. exp neoplasms/ (2334147)
3. 1 and 2 (1100)
4. ((edmonton or Memorial) adj2 Symptom* adj2
Assess* adj2 (Scale* or instrument* or screen*)).mp.
(211)
5. 3 and 4 (1151)
6. limit 5 to "all child (0 to 18 years)" (120)
EMBASE <1980 to 2011 Week 50>
1. (Symptom* adj2 (Scale* or instrument* or screen* or
measure* or tool or tools or checklist*)).mp. or
symptom checklist 90/ or symptom distress scale/ or
brief symptom inventory/ or ((edmonton or
Memorial) adj2 Symptom* adj2 Assess* adj2 (Scale*
or instrument* or screen*)).mp. (21462)
2. physical disease by body function/ or constipation/ or
exp coughing/ or exp cyanosis/ or exp diarrhea/ or
exp faintness/ or exp fatigue/ or exp incontinence/ or
listlessness/ or malaise/ or exp "nausea and
vomiting"/ or exp pain/ or pallor/ or weakness/
(954957)
3. checklist/ or clinical assessment tool/ or rating scale/
or scoring system/ or exp screening/ or summated
rating scale/ or self report/ (572563)
4. 1 or (2 and 3) (68751)
5. exp neoplasm/ or cancer patient/ or exp terminally ill
patient/ (2708653)
6. 4 and 5 (9312)
7. limit 6 to (infant < to one year > or child < unspecified
age > or preschool child <1 to 6 years > or school child
<7 to 12 years > or adolescent <13 to 17 years>) (628)
Abbreviations
ESAS: Edmonton Symptom Assessment Scale; QoL: Quality of life.
Competing interests
The authors declare that they have no competing interests.Authors’ contributions
LLD, DT, MCE, TH and LS have made substantial contributions to study
conception and design, acquisition of data and analysis and interpretation of
data. All have been involved in drafting and critical revision of the
manuscript for important intellectual content and have given final approval
of the version to be published.Acknowledgements
LS is supported by a New Investigator Award from the Canadian Institutes of
Health Research.
Author details
1Department of Pharmacy, The Hospital for Sick Children, 555 University
Avenue, Toronto, ON M5G 1X8, Canada. 2Program in Child Health Evaluative
Sciences, The Hospital for Sick Children, 555 University Avenue, Toronto, ON
M5G 1X8, Canada. 3Division of Haematology/Oncology, The Hospital for Sick
Children, 555 University Avenue, Toronto, ON M5G 1X8, Canada. 4Leslie Dan
Faculty of Pharmacy, University of Toronto, Toronto, Canada.
Received: 8 February 2012 Accepted: 19 September 2012
Published: 26 September 2012References
1. Baggott C, Dodd M, Kennedy C, Marina N, Matthay KK, Cooper BA,
Miaskowski C: Changes in children's reports of symptom occurrence and
severity during a course of myelosuppressive chemotherapy. J Pediatr
Oncol Nurs 2010, 27(6):307–315.
2. Miller E, Jacob E, Hockenberry MJ: Nausea, pain, fatigue, and multiple
symptoms in hospitalized children with cancer. Oncol Nurs Forum 2011,
38(5):E382–393.
3. Poder U, Ljungman G, von Essen L: Parents' perceptions of their children's
cancer-related symptoms during treatment: a prospective, longitudinal
study. J Pain Symptom Manage 2010, 40(5):661–670.
4. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows
AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, et al: Chronic
health conditions in adult survivors of childhood cancer. N Engl J Med
2006, 355(15):1572–1582.
5. Taddio A, Katz J: The effects of early pain experience in neonates on pain
responses in infancy and childhood. Paediatr Drugs 2005, 7(4):245–257.
6. Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D:
Changing patient perceptions of the side effects of cancer
chemotherapy. Cancer 2002, 95(1):155–163.
7. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, Tattersall
MH: On the receiving end–patient perception of the side-effects of
cancer chemotherapy. Eur J Cancer Clin Oncol 1983, 19(2):203–208.
8. de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, v Beurden V, Stoter G,
Verweij J: Patient perceptions of the side-effects of chemotherapy: the
influence of 5HT3 antagonists. Br J Cancer 1997, 76(8):1055–1061.
9. Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, Tattersall
MH: On the receiving end. V: Patient perceptions of the side effects of
cancer chemotherapy in 1993. Ann Oncol 1996, 7(2):189–195.
10. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K: The Edmonton
Symptom Assessment System (ESAS): a simple method for the
assessment of palliative care patients. J Palliat Care 1991, 7(2):6–9.
11. Ontario Cancer Symptom Management Collaborative. https://www.
cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=57595.
12. World Health Organization: World Health Organization Constitution. Geneva:
World Health Organization; 1948.
13. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke
JP: The Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) statement: guidelines for reporting
observational studies. J Clin Epidemiol 2008, 61(4):344–349.
14. Landis JR, Koch GG: The measurement of observer agreement for
categorical data. Biometrics 1977, 33:159–174.
15. Hayden JA, Cote P, Bombardier C: Evaluation of the quality of prognosis
studies in systematic reviews. Ann Intern Med 2006, 144(6):427–437.
16. Gibson F, Aldiss S, Taylor RM, Maguire R, McCann L, Sage M, Kearney N:
Utilization of the Medical Research Council evaluation framework in the
development of technology for symptom management: the ASyMS-YG
Study. Cancer Nurs 2010, 33(5):343–352.
Dupuis et al. BMC Cancer 2012, 12:430 Page 6 of 6
http://www.biomedcentral.com/1471-2407/12/43017. Dupuis LL, Milne-Wren C, Cassidy M, Barrera M, Portwine C, Johnston DL,
Silva MP, Sibbald C, Leaker M, Routh S, et al: Symptom assessment in
children receiving cancer therapy: the parents' perspective. Support Care
Cancer 2010, 18(3):281–299.
18. Baggott CR, Dodd M, Kennedy C, Marina N, Matthay KK, Cooper B,
Miaskowski C: An evaluation of the factors that affect the health-related
quality of life of children following myelosuppressive chemotherapy.
Support Care Cancer 2011, 19(3):353–361.
19. Wu WW, Johnson R, Schepp KG, Berry DL: Electronic self-report symptom
and quality of life for adolescent patients with cancer: a feasibility study.
Cancer Nurs 2011, 34(6):479–486.
20. Walker AJ, Gedaly-Duff V, Miaskowski C, Nail L: Differences in symptom
occurrence, frequency, intensity, and distress in adolescents prior to and
one week after the administration of chemotherapy. J Pediatr Oncol Nurs
2010, 27(5):259–265.
21. Sitaresmi MN, Mostert S, Purwanto I, Gundy CM, Sutaryo, Veerman AJ:
Chemotherapy-related side effects in childhood acute lymphoblastic
leukemia in Indonesia: parental perceptions. J Pediatr Oncol Nurs 2009,
26(4):198–207.
22. Yeh CH, Wang CH, Chiang YC, Lin L, Chien LC: Assessment of symptoms
reported by 10- to 18-year-old cancer patients in Taiwan. J Pain Symptom
Manage 2009, 38(5):738–746.
23. Williams PD, Schmideskamp J, Ridder EL, Williams AR: Symptom
monitoring and dependent care during cancer treatment in children:
pilot study. Cancer Nurs 2006, 29(3):188–197.
24. Collins JJ, Devine TD, Dick GS, Johnson EA, Kilham HA, Pinkerton CR,
Stevens MM, Thaler HT, Portenoy RK: The measurement of symptoms in
young children with cancer: the validation of the Memorial Symptom
Assessment Scale in children aged 7–12. J Pain Symptom Manage 2002,
23(1):10–16.
25. Hinds PS, Schum L, Srivastava DK: Is clinical relevance sometimes lost in
summative scores? West J Nurs Res 2002, 24(4):345–353.
26. Collins JJ, Byrnes ME, Dunkel IJ, Lapin J, Nadel T, Thaler HT, Polyak T, Rapkin
B, Portenoy RK: The measurement of symptoms in children with cancer.
J Pain Symptom Manage 2000, 19(5):363–377.
27. Berard RM, Boermeester F: Psychiatric symptomatology in adolescents
with cancer. Pediatr Hematol Oncol 1998, 15(3):211–221.
28. Eiser C, Havermans T, Craft A, Kernahan J: Validity of the Rotterdam
symptom checklist in paediatric oncology. Med Pediatr Oncol 1997,
28(6):451–454.
29. de Haes JCJM, Olschewski M, Fayers P, Visser MRM, Cull A, Hopwood P,
Sanderman R: The Rotterdam Symptom Checklist: A manual. The Netherlands:
Northern Centre for Healthcare Research (NCH), University of Groningen; 1996.
30. Woodgate RL: Children's cancer symptom experiences: keeping the spirit
alive in children and their families. . . The 2002 Schering Lecture, 14th
Annual CANO Conference – sponsored by Schering Canada. Can Oncol
Nurs J 2003, 13(3):142–150.
doi:10.1186/1471-2407-12-430
Cite this article as: Dupuis et al.: A systematic review of symptom
assessment scales in children with cancer. BMC Cancer 2012 12:430.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
